CCCC C4 Therapeutics, Inc.
Company Analysis
Latest News
C4 Therapeutics second quarter 2026 results show $300M cash position and narrowed net loss
C4 Therapeutics reported a narrowed net loss for the second quarter 2026, driven by lower personnel-related stock-based compensation and a slight increase in...
C4 Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Analysts expect C4 Therapeutics to report Q2 2026 revenue of $8.20 million and a loss of $0.23 per share, with the current stock price of $3.62 trading...
🔴 C4 Therapeutics is trading 5.8% down today with no clear catalyst
C4 Therapeutics is trading 5.8% down at $4.04 today on light news flow, with no fresh company-specific developments reported on July 10. * There are no new...
🔴 CCCC makes sharp 10.2% drop
CCCC is trading at $3.90, down 10.2% versus the comparison close of $4.35 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 CCCC is trading 5.2% down today on profit-taking following its myeloma data rally
CCCC is trading 5.2% down at $4.12 as investors lock in profits following a sharp rally driven by clinical trial results. • The stock's recent gains were...
🟢 CCCC is trading 5.6% up today on renewed interest in Phase 1 cemsidomide data
CCCC is trading 5.6% up at $4.37 following renewed interest in Phase 1 cemsidomide data for relapsed/refractory multiple myeloma. • Updated clinical results...
🔴 CCCC makes sharp 10.1% drop
CCCC is trading at $4.20, down 10.1% versus the comparison close of $4.67 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 CCCC is trading 5.4% down today on profit-taking after recent clinical data-driven rally
CCCC is trading approximately 5.4% down at $4.42 today as investors lock in gains following a sharp clinical data-driven rally. • The stock recently surged on...
🟢 CCCC makes sharp 10.5% jump
CCCC is trading at $4.80, up 10.5% versus the comparison close of $4.35 during regular trading. This is a price-movement alert; no separate company-specific...
C4 Therapeutics Gets an Analyst Upgrade — But Can a $4 Biotech Stock Deliver on Its Billion-Dollar Drug Ambitions?
Shares shifted as C4 Therapeutics climbed 7.4% to $4.67 after the clinical-stage biotech was upgraded to a Zacks Rank #2 (Buy), a signal that Wall Street's...
🟢 CCCC is trading 7.4% up today on a Zacks Rank upgrade and improved earnings sentiment
CCCC is trading 7.4% up at $4.67 following a recent analyst upgrade and strengthening sentiment toward its earnings outlook. • The stock was recently elevated...
🔴 CCCC is trading 5.6% down today on potential profit-taking after recent gains
CCCC is trading 5.6% down today at $4.16, appearing to face short-term volatility and profit-taking following several days of gains earlier this week. *...
C4 Therapeutics Shareholders Approve Amendment to 2020 Stock Incentive Plan
C4 Therapeutics announced the results of its Annual Meeting of Stockholders held on June 24, 2026, where shareholders approved an amendment to the company's...
🟢 CCCC is trading 8.1% up today, extending its recent uptrend despite no clear catalyst
CCCC is trading 8.1% up today at $4.46, extending its strong recent uptrend despite a lack of fresh company-specific news. • No new press releases, FDA...
🟢 C4 Therapeutics Inc is trading 5.2% up today as company presents positive Phase 1 cemsidomide data
C4 Therapeutics Inc is trading 5.2% up today at $4.04 following the presentation of positive Phase 1 data for its cemsidomide drug at the European Hematology...
🔴 C4 Therapeutics Inc is trading 5.2% down today amid a lack of clear catalysts
C4 Therapeutics Inc is trading 5.2% down at $3.62 today amid a lack of fresh, company-specific news or filings pointing to a clear catalyst for the move. •...
🟢 C4 Therapeutics Inc is trading 5.1% up today on positive Phase 1 multiple myeloma data
C4 Therapeutics Inc is trading 5.1% up at $4.10 in after-hours trading following the presentation of positive Phase 1 data for its CELMoD degrader,...
🟢 C4 Therapeutics Inc is trading 5.7% up today on positive EHA data for cemsidomide in multiple myeloma
C4 Therapeutics Inc is trading 5.7% up at $4.09 following the presentation of positive Phase 1 data for cemsidomide at the EHA Congress. • The trial for...
Reports 53% Overall Response Rate in Phase 1 Cemsidomide Trial for Multiple Myeloma
C4 Therapeutics presented further analysis from its fully enrolled Phase 1 trial of cemsidomide for relapsed/refractory multiple myeloma (RRMM) at the European...
🟢 C4 Therapeutics Inc is trading 5.2% up today as buying interest grows ahead of Goldman Sachs healthcare conference
C4 Therapeutics Inc is trading 5.2% higher at $3.77 as buying interest picks up ahead of management's participation in the Goldman Sachs 47th Annual Global...